ArticleFrontiers in cardiovascular medicine2025
Contrast echocardiography with a physiological contrast agent for alcohol septal ablation.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Myocardial contrast echocardiography in alcohol septal ablation (ASA) is critical prior to alcohol injection into the target septal artery branch. However, current contrast agents are expensive, carry the risk of anaphylaxis reaction, and are widely unavailable. Against this background, in this study, we introduce a practical solution for the assessment of target septal arteries by using physiological, practical, and safer intracoronary injections. Methods: This study included 14 patients (8 females, 6 males), with symptomatic hypertrophic obstructive cardiomyopathy who underwent ASA between the years 2017 and 2025. Because of the unavailability and the high cost of contrast agents in our country, we used practical physiological agents, which comprised a cocktail fluid (agitated 5 mL of saline plus 0.5 mL blood of the patient). We injected ethanol (absolute alcohol 96%-99%) into the target perforatory artery using transesophageal echocardiography (TEE) in a step-by-step manner to observe a reduction in mitral regurgitation and QT prolongation at electrocardiographic monitorization (initially, 0.5 mL alcohol, then by increasing the dosage up to 3 mL). Results: We clearly obtained a good myocardial opacification of the interventricular basal septum border with our cocktail contrast agent. Furthermore, we used TEE in the ASA procedure, unlike other researchers who reported on this procedure. No arrhythmias and allergic reactions were recorded during the administration of the contrast agent. The mean dose of alcohol administered during ASA was 2.1 ± 0.7 mL. The procedural rate of success was highest (100%). We assessed the effectiveness of the treatment in terms of a reduction of the peak left ventricular outflow tract gradient and the disappearance of severe mitral regurgitation with a significantly systolic anterior motion. Conclusions: The use of a physiological cocktail fluid in TEE exemplifies the use of a practical, alternative myocardial contrast agent for alcohol septal ablation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.